<DOC>
	<DOCNO>NCT00718913</DOCNO>
	<brief_summary>This study determine feasibility adjuvant chemotherapy chemo-radiotherapy patient surgically resect adenocarcinoma stomach gastro-esophageal junction .</brief_summary>
	<brief_title>Postoperative Chemotherapy Chemo-radiotherapy Resected Gastric Cancer</brief_title>
	<detailed_description>Patients localize gastric cancer often relapse either locally systemically . A strategy reduce relapse common site would beneficial . Our prior trial prove feasibility administer FOLFIRI regimen adjuvant chemotherapy combine adjuvant chemoradiation patient excise curative intend gastric cancer . It would important improve treatment involve active regimen adjuvant chemotherapy optimize chemoradiation introduce capecitabine radiosensitizer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients radically resect adenocarcinoma stomach and/or gastroesophageal junction histologic proof adenocarcinoma , pathologically stag T23 , N , M0 No prior radiation therapy stomach immunotherapy chemotherapy reason Patients must life expectancy least 16 week performance status &lt; 2 ECOG scale Previous adjuvant chemotherapy Irinotecan , Oxaliplatin and/or 5FU base regimen . Patients relapse within first 6 month completion adjuvant treatment eligible study . Patients must adequate bone marrow function ( defined peripheral absolute granulocyte count &gt; 2.000/µL , platelet count &gt; 100.000/µL ) , adequate liver function ( bilirubin &lt; 1,5 mg/dl ) , adequate renal function ( creatinine &lt; 1,5 mg/dl Patients must able understand nature study give write informed consent Patients T1N0 carcinoma Positive cytology pleural , pericardial effusion patient peritoneal disease diagnose intraoperatively ) Biopsy proof lymph node metastasis outside study field supraclavicular , mediastinal , paraaortic node Evidence metastatic disease distant organs Patients cardiac disease grade New York Heart Association Class III IV , severe uncontrolled diabetes , hypertension , cerebronvascular disease , infection Patients diabetic neuropathy Abnormalities mental status either patient fully comprehend therapeutic implication protocol comply requirement Presence concurrent previous malignancy past 5 year ( except resect squamous basal cell carcinoma skin ) Pregnant woman exclude study entry due teratogenic effect study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Adjuvant Gastric Cancer</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Adjuvant chemo-radiation</keyword>
	<keyword>Capecitabine</keyword>
</DOC>